Changes in ocular signs and symptoms when switching from preserved latanoprost 0.005% to preservative-free tafluprost 0.0015%: phase IIIb study in patients with open-angle glaucoma or ocular hypertension

Purpose This open-label, multinational, phase IIIb study investigated the changes in ocular signs and symptoms when patients were switched from preserved latanoprost 0.005% to preservative-free tafluprost 0.0015% (q.d. at 20:00) for 12 weeks. Methods Patients with open-angle glaucoma or ocular hypertension who had received latanoprost for at least 6 months and had at least 2 ocular symptoms or one symptom and one sign were enrolled (n=158). Change from screening in ocular symptoms and signs were the main endpoints. Data from the 6-week analysis are reported here. Results After switching to preservative-free tafluprost, the proportion of patients with at least mild symptoms decreased: irrita…